These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 386073

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D.
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [Abstract] [Full Text] [Related]

  • 3. Investigational trials of anticancer drugs: establishing safeguards for experimentation.
    Chabner BA, Wittes R, Hoth D, Hubbard S.
    Public Health Rep; 1984 Mar; 99(4):355-60. PubMed ID: 6431482
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The role of the National Cancer Institute in drug development.
    Doroshow J.
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract] [Full Text] [Related]

  • 6. Increasing access to investigational drugs.
    Christian M.
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):90-1. PubMed ID: 16163167
    [No Abstract] [Full Text] [Related]

  • 7. Slow start to phase 0 as researchers debate value.
    Twombly R.
    J Natl Cancer Inst; 2006 Jun 21; 98(12):804-6. PubMed ID: 16788150
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. NIH Consensus Development Conference summary: Adjuvant Chemotherapy of Breast Cancer.
    J Tenn Med Assoc; 1981 Mar 21; 74(3):190-2. PubMed ID: 7024644
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R.
    J Natl Cancer Inst; 2005 May 18; 97(10):708-9. PubMed ID: 15900036
    [No Abstract] [Full Text] [Related]

  • 12. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S, Wittes R.
    Cancer Treat Rep; 1984 Jan 18; 68(1):77-85. PubMed ID: 6362870
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical trials: a recent emphasis in the prevention program of the National Cancer Institute.
    DeWys WD, Greenwald P.
    Semin Oncol; 1983 Sep 18; 10(3):360-4. PubMed ID: 6665563
    [No Abstract] [Full Text] [Related]

  • 16. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
    Cancer Treat Rep; 1984 Jan 18; 68(1):343-56. PubMed ID: 6692435
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.